Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
Top Cited Papers
- 1 October 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 362 (9391) , 1184-1191
- https://doi.org/10.1016/s0140-6736(03)14541-2
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Effect of interferon-?1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trialAnnals of Neurology, 1999
- Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosisAnnals of Neurology, 1999
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosisAnnals of Neurology, 1998
- Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosisNeurology, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisPublished by Elsevier